Tempus AI Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
TEM$84.44+11.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description of Exhibit | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-42130 | 3.1 | June 17, 2024 |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K | 001-42130 | 3.2 | June 17, 2024 |
| 10.1 | Twelfth Amended and Restated Investor Rights Agreement, dated April 30, 2024 | S-1 | 333-279558 | 10.1 | May 20, 2024 |
| 10.2# | The Registrant’s 2024 Equity Incentive Plan. | S-1 | 333-279558 | 10.4 | May 20, 2024 |
| 10.3# | Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Registrant’s 2024 Equity Incentive Plan. | S-1 | 333-279558 | 10.5 | May 20, 2024 |
| 10.4# | Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Registrant’s 2024 Equity Incentive Plan. | S-1 | 333-279558 | 10.6 | May 20, 2024 |
| 10.5# | Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officers. | S-1 | 333-279558 | 10.7 | May 20, 2024 |
| 10.6# | The Registrant’s 2024 Employee Stock Purchase Plan. | S-1 | 333-279558 | 10.17 | May 20, 2024 |
| 10.7† | Joint Venture Agreement, by and among Softbank Group Corporation, Softbank Group Japan Corporation, the Registrant and Pegasos Corp., dated May 18, 2024. | S-1/A | 333-279558 | 10.27 | June 5, 2024 |
| 10.8† | Data License Agreement by and between the Registrant and Pegasos Corp., dated May 18, 2024. | S-1/A | 333-279558 | 10.28 | June 5, 2024 |
| 10.9† | Intellectual Property License Agreement, by and between the Registrant and Pegasos Corp., dated May 18, 2024. | S-1/A | 333-279558 | 10.29 | June 5, 2024 |
| 10.10† | Amendment No. 1 to Strategic Collaboration Agreement, by and between the Registrant and GlaxoSmithKline LLC, dated May 20, 2024. | S-1/A | 333-279558 | 10.30 | June 5, 2024 |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*+ | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Document. | ||||
| 104* | Cover Page formatted as inline XBRL and contained in Exhibit 101. | ||||
| * | Filed herewith |
|---|
| + | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended. |
|---|
| # | Indicates a management contract or any compensatory plan, contract or arrangement. |
|---|
| † | Certain portions of this exhibit (indicated by asterisks) have been omitted because they are not material and are the type that the registrant treats as private or confidential. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.